Óêðàèíñêèé ïóëüìîíîëîãè÷åñêèé æóðíàë |
||||||||||||
Îá èíñòèòóòå: ëå÷åáíî-äèàãíîñòè÷åñêàÿ ðàáîòà, Íîâîñòè: Íàøè èçäàíèÿ: "Óêðàèíñêèé
ïóëüìîíîëîãè÷åñêèé æóðíàë" (ÓÏÆ), Îðèãèíàëüíûå ñòàòüè: îðèãèíàëüíûå íàó÷íûå ñòàòüè, ðàíåå íèãäå íå ïóáëèêîâàâøèåñÿ Íîâîââåäåíèÿ:
ìåòîäè÷åñêèå ðåêîìåíäàöèè,
èíôîðìàöèîííûå ïèñüìà, Ïàòåíòû: ïàòåíòû è àâòîðñêèå ñâèäåòåëüñòâà èíñòèòóòà Îò÷åòû î ÍÈÐ: ðåôåðàòû çàêîí÷åííûõ íàó÷íî-èññëåäîâàòåëüñêèõ ðàáîò Ïîäãîòîâêà êàäðîâ:
êëèíè÷åñêàÿ îðäèíàòóðà, â ïîìîùü àñïèðàíòó è ñîèñêàòåëþ Íàó÷íûå ôîðóìû: ðåçîëþöèè è îáðàùåíèÿ ñúåçäîâ, êîíôåðåíöèé, ñîâåùàíèé... Âèðòóàëüíûå êîíôåðåíöèè: âîïðîñû è îòâåòû ïî ïðîáëåìàì çàáîëåâàíèé îðãàíîâ äûõàíèÿ Èíôîðìàöèÿ äëÿ ñïåöèàëèñòîâ: Èíôîðìàöèÿ äëÿ íàñåëåíèÿ: ïîëåçíàÿ
èíôîðìàöèÿ î çàáîëåâàíèÿõ ëåãêèõ, èõ ïðîôèëàêòèêå è ëå÷åíèè |
2014. - ¹
2.
|
Þ. Ì. Ìîñòîâîé
ÖÈÔÐÈ, ÙÎ ÃÎÂÎÐßÒÜ ² ÌÎÂ×ÀÒÜ: ÐÎÇÄÓÌÈ ÏÐÎ ÕÎÇË, ÙÎ ÁÀÇÓÞÒÜÑß ÍÀ
ÑÒÀÒÈÑÒÈ×ÍÎÌÓ ÀÍÀ˲Ç
®
Yu. M. Mostovoy
FIGURES WHICH SPEAKS AND KEEP SILENCE: REFLECTIONS ON COPD BASED ON
STATISTICAL ANALYSIS
È. È. Âèøíèâåöêèé
ÕÎÇË Â ÓÊÐÀÈÍÅ: ×ÅÃÎ ÌÛ ÎÏÀÑÀÅÌÑß? ÂÎÏÐÎÑÛ ÁÅÇÎÏÀÑÍÎÑÒÈ ÈÍÃÀËßÖÈÎÍÍÛÕ
ÑÐÅÄÑÒÂ
®
I. I. Vishnivetskiy
COPD IN UKRAINE: WHAT ARE WE REALLY AFRAID OF? SAFETY OF INHALED MEDICINES
Ò. À. Ïåðöåâà
ÒÅÐÀÏÈß ÕÎÇË: Ê ×ÅÌÓ ÍÀÄÎ ÑÒÐÅÌÈÒÜÑß?
®
T. A. Pertseva
COPD THERAPY: WHAT SHOULD WE STRIVE FOR?
MODERN APPROACHES TO PREVENTION AND TREATMENT OF OBSTRUCTIVE LUNG DISEASES
(a symposium, supported by Boehringer Ingelheim)
V. K. Gavrisiuk, A. I. Yachnik, E. A. Merenkova
COR PULMONLE IN LIGHT OF INTERNATIONAL NICE-COPD AND GOLD GUIDELINES
Í. Å.
Ìîíîãàðîâà
ÂÛÁÎÐ ÒÅÐÀÏÈÈ Ó ÏÀÖÈÅÍÒÎÂ Ñ ÂÛÑÎÊÈÌ ÐÈÑÊÎÌ ÎÁÎÑÒÐÅÍÈß ÕÎÇË
®
N. E. Monogarova
CHOICE OF THERAPY IN PATIENTS WITH HIGH RISK OF COPD EXACERBATION
L.I. Konopkina
EFFECT OF COMPLIANCE ON RESULTS OF TREATMENT OF COPD PATIENTS
A.P. Grishilo
USE OF INNOVATIVE STRUCTURE OF FLUTICASONE PROPIONATE IN TREATMENTS OF COPD
PATIENTS
Ë. À. ßøèíà
ÄÎÊÀÇÀÒÅËÜÍÀß ÁÀÇÀ ÝÔÔÅÊÒÈÂÍÎÑÒÈ ÃËÈÊÎÏÈÐÎÍÈß Ó ÏÀÖÈÅÍÒÎÂ Ñ ÕÎÇË
®
L. A. Yashina
EVIDENCES OF EFFICIENCY OF GLYCOPYRRONIUM IN COPD PATIENTS
T. A. Pertseva
SEEBRI BREETHHALER — NEW ANTIMUSCARINIC AGENT: CHOICE OF OPTIMUM TREATMETN
OF COPD PATIENTS
M. M. Ostrowski
SEEBRI BREETHHALER — NOVEL OPPORTUNITIES AND THE WAYS OF IMPROVEMENT OF
SYMPTOMS AND EXACERBATOINS CJNTROL
Ñ. È. Ëåùåíêî
ÍÎÂÛÅ ÏÅÐÑÏÅÊÒÈÂÛ ÐÀÇÂÈÒÈß ÎÒÅ×ÅÑÒÂÅÍÍÎÉ ÈÍÃÀËßÖÈÎÍÍÎÉ ÒÅÐÀÏÈÈ
®
S.I. Leshchenko
PERSPECTIVES OF DEVELOPMENT OF DOMESTIC INHALATION MEDICINE
ÎÐÈòÍÀËÜͲ ÑÒÀÒÒ² / ORIGINALS
Â. À. ß÷íèê
ÑÏÅÊÒÐ ÒÀ ÐÎËÜ ²ÍÔÅÊÖ²ÉÍÈÕ ÇÁÓÄÍÈʲ ÏÐÈ ÇÀÃÎÑÒÐÅÍͲ ÁÐÎÍÕ²ÀËÜÍί ÀÑÒÌÈ
®
V. A.
Iachnyk
SPECTRUM AND ROLE OF INFECTIOUS AGENTS IN ACUTE ASTHMA EXACERBATION
ß. Î. Äçþáëèê
ÐÀÖ²ÎÍÀËÜÍÀ ÀÍÒÈÁ²ÎÒÈÊÎÒÅÐÀÏ²ß ÕÂÎÐÈÕ ÍÀ ÍÅÃÎÑϲÒÀËÜÍÓ ÏÍÅÂÌÎÍ²Þ ²²²
Ê˲Ͳ×Íί ÃÐÓÏÈ
®
Ya. O.
Dziublyk
RATIONAL ANTIBIOTIC THERAPY OF GROUP III COMMUNITY-ACQUIRED PNEUMONIA
PATIENTS
ÑÒÀÍÄÀÐÒÈ Ä²ÀÃÍÎÑÒÈÊÈ ÒÀ ˲ÊÓÂÀÍÍß / STANDARDS FOR DIAGNOSIS
AND TREATMENT
²ÍÔÎÐÌÀÖ²ß / INFORMATION
ÐÅÇÎËÞÖ²ß
ÍÀÐÀÄÈ ÅÊÑÏÅÐÒ²Â Ç ÏÓËÜÌÎÍÎËÎò¯ «ÑÓ×ÀÑͲ ϲÄÕÎÄÈ ÒÀ Íβ ÌÎÆËÈÂÎÑÒ² Â
˲ÊÓÂÀÍͲ ÕÎÇË»
®
RESOLUTION OF BOARD OF PULMONOLOGY EXPERTS «CURRENT APPROACHES AND NOVEL
OPPORTUNITIES IN COPD THERAPY»
ÏÐÎÖÞÊ ÐÀÄÓ
ÃÅÎÐòÉÎÂÈ× (äî 75-ð³÷÷÷ÿ â³ä äíÿ íàðîäæåííÿ)
®
PROTSIUK R. G. (75 years anniversary)
ÎÐÈòÍÀËÜͲ ÑÒÀÒÒ² / ORIGINALS
Ê˲Ͳ×Ͳ ÑÏÎÑÒÅÐÅÆÅÍÍß / CLINICAL OBSERVATIONS
²ÍÔÎÐÌÀÖ²ß / INFORMATION
ÀÂÒÎÐÀÌ ÆÓÐÍÀËÜÍÈÕ ÏÓÁ˲ÊÀÖ²É
®
INSTRUCTIONS TO THE AUTHORS
Home •
Ïîèñê •
Ïðî èíñòèòóò • Íîâîñòè •
Íàøè èçäàíèÿ •
Îðèãèíàëüíûå ñòàòòüè •
Íîâîââåäåíèÿ
Ïàòåíòû •
Îò÷åòû î ÍÄÐ •
Ïîäãîòîâêà êàäðîâ • Íàó÷íûå
ôîðóìû
Èíôîðìàöèÿ äëÿ ñïåöèàëèñòîâ •
Èíôîðìàöèÿ äëÿ íàñåëåíèÿ •
Ìåäèöèíñêèå óñëóãè